Axovan

Allschwil, Switzerland Founded: 2000 • Age: 26 yrs Acquired By Actelion
Drug development company specializing in G Protein-Coupled Receptors (GPCRs) targeting therapeutics
Request Access

About Axovan

Axovan is a company based in Allschwil (Switzerland) founded in 2000 was acquired by Actelion in September 2003.. Axovan has raised $23.31 million across 2 funding rounds from investors including Actelion, Atlas Venture and Heidelberg Innovationsfonds Management. Axovan operates in a competitive market with competitors including Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others.

  • Headquarter Allschwil, Switzerland
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $23.31 M (USD)

    in 2 rounds

  • Latest Funding Round
    $18.4 M (USD), Series B

    Apr 26, 2002

  • Investors
    Actelion

    & 2 more

  • Employee Count
    Employee Count
  • Acquired by
    Actelion

    (Sep 30, 2003)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Axovan

Axovan has successfully raised a total of $23.31M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $18.4 million completed in April 2002. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 2
  • Last Round Series B — $18.4M
  • First Round

    (01 Jun 2000)

  • Investors Count 2
Date Amount Transaction Name Valuation Lead Investors Investors
Apr, 2002 Amount Series B - Axovan Valuation Atlas Venture
Jun, 2000 Amount Series A - Axovan Valuation Heidelberg Innovationsfonds Management
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Axovan

Axovan has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Actelion, Atlas Venture and Heidelberg Innovationsfonds Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital firm investing in life science and biotechnology sectors
Founded Year Domain Location
-
Founded Year Domain Location
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Axovan

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Axovan

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Axovan Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Axovan

Axovan operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Portola Pharma, MyoKardia, Cellino, Arrakis Therapeutics and Tenaya Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Therapeutics for cardiovascular and autoimmune diseases are developed.
domain founded_year HQ Location
Specialized drugs are developed for genetic heart diseases.
domain founded_year HQ Location
Developer of autologous cell therapies
domain founded_year HQ Location
Provider of tools for the analysis of RNA structures
domain founded_year HQ Location
Regenerative and gene therapeutics for heart failure are developed.
domain founded_year HQ Location
Innovative pharmaceuticals for cardiovascular and metabolic diseases are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Axovan

Frequently Asked Questions about Axovan

When was Axovan founded?

Axovan was founded in 2000.

Where is Axovan located?

Axovan is headquartered in Allschwil, Switzerland. It is registered at Allschwil, Basel-landschaft, Switzerland.

Is Axovan a funded company?

Axovan is a funded company, having raised a total of $23.31M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4.91M, raised on Jun 01, 2000.

What does Axovan do?

Axovan AG was a drug development company specializing in G Protein-Coupled Receptors (GPCRs). The company had a fully functional drug discovery platform and a growing portfolio of drug candidates targeting GPCRs for various indications. At the time of acquisition, its most advanced project is a drug called clazosentan (aims to prevent cerebral vasospasm, or sharp contractions of the blood vessels, which can occur after a certain type of brain hemorrhage), which it licensed from Roche Holding AG. The drug was in Phase II of clinical testing, which monitors effectiveness and safety on a limited number of patients, and the same class as Actelions Tracleer.

Who are the top competitors of Axovan?

Axovan's top competitors include Tenaya Therapeutics, Cellino and MyoKardia.

Who are Axovan's investors?

Axovan has 3 investors. Key investors include Actelion, Atlas Venture, and Heidelberg Innovationsfonds Management.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available